Covered recipient · General Payments record
WESLEY WARD
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2022–2024
$597.90
- Reported across 32 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $326.71 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $184.37 | 9 |
| Axsome Therapeutics, Inc. | $44.39 | 2 |
| Teva Pharmaceuticals USA, Inc. | $39.44 | 2 |
| Otsuka America Pharmaceutical, Inc. | $20.53 | 1 |
| Supernus Pharmaceuticals, Inc. | $19.87 | 1 |
| Alkermes, Inc. | $18.11 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $31.64 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108379299 | CMS |
| ABBVIE INC. | $11.79 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108379301 | CMS |
| ABBVIE INC. | $13.75 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108379303 | CMS |
| ABBVIE INC. | $27.60 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108379305 | CMS |
| ABBVIE INC. | $31.42 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108379307 | CMS |
| ABBVIE INC. | $19.43 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108379309 | CMS |
| ABBVIE INC. | $5.96 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108379311 | CMS |
| ABBVIE INC. | $25.26 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108379313 | CMS |
| ABBVIE INC. | $17.52 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108379315 | CMS |
| Alkermes, Inc. | $18.11 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120616822 | CMS |
| Axsome Therapeutics, Inc. | $24.87 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148419207 | CMS |
| Axsome Therapeutics, Inc. | $19.52 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148419209 | CMS |
| Otsuka America Pharmaceutical, Inc. | $20.53 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119210073 | CMS |
| Supernus Pharmaceuticals, Inc. | $19.87 | 12/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147901686 | CMS |
| Teva Pharmaceuticals USA, Inc. | $25.52 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151652567 | CMS |
| Teva Pharmaceuticals USA, Inc. | $13.92 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151652706 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.